ABCL Stock Analysis: Buy, Sell, or Hold?
ABCL - AbCellera Biologics Inc. Common Shares
$3.25
-0.02 (-0.61%)
▼
5d:
-3.56%
30d:
-9.97%
90d:
-9.22%
HOLD
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Smart Money Accumulation
ABCL is down 4.5% this week, but smart money is accumulating calls. Top strike: $5 2026-04-17 with 7,112 OI. Call ratio: 84% View Scanner →
Strength: 5.7/10
Get Alerted When ABCL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ABCL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ABCL is currently trading at $3.25, which is considered slightly low relative to its 30-day fair value range of $3.25 to $3.63.
Technical Outlook: Technically, ABCL is in a strong uptrend. The price is currently testing key support at $3.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABCL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.17 (+180.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABCL is in a strong uptrend. The price is currently testing key support at $3.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ABCL has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $9.17 (+180.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$3.25 -
$3.63
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 180.3% below Wall St target ($9.17)
Fair Price Analysis
30-Day Fair Range
$3.25 -
$3.63
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.24
Resistance Level
$3.59
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.25
Wall Street Target
$9.17
(+180.3%)
Revenue Growth (YoY)
788.2%
Earnings Growth (YoY)
45.9%
Profit Margin
-194.9%
Share & Embed Analysis
Last updated: March 30, 2026 1:36 PM ET
Data refreshes hourly during market hours. Next update: 2:36 PM
Data refreshes hourly during market hours. Next update: 2:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABCL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 56 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$290 | 47 HOLD |
